INTERVIEW: Korea Initiative Aims To Create Global Clinical Trial Hub
This article was originally published in PharmAsia News
In a recent interview with PharmAsia News, the head of the Korea Clinical Trial Global Initiative stressed the importance of continued government support in boosting the country’s competitiveness in clinical trials, amid narrowing gaps with its Asian rivals. He also talked about why the initiative is focusing on attracting early phase work from foreign firms and what South Korea needs to do to maintain its edge.
You may also be interested in...
South Korean clinical trial data for 2016 reflects the global boom in biologics R&D and the decline in development of synthetic drugs. A series of clinical trial failures by major South Korean pharmaceutical firms may also have weakened overall drug development activities.
EyeGene R&D head talks to Scrip at CPhI Korea about the development of its COVID-19 vaccine candidate EG-COVID, potential challenges in clinical trials and positioning and the over-riding importance of validating a viable mRNA platform.
EuBiologics CEO Yeong Ok Baik sat down with Scrip at CPhI Korea to talk about why he wants to develop vaccines for global public health needs and what plans are in store for its late-stage recombinant protein candidate for COVID-19.